

13/12/2006,10521325b.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTASXY1626

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'HCAPLUS' AT 14:06:29 ON 07 DEC 2006  
FILE 'HCAPLUS' ENTERED AT 14:06:29 ON 07 DEC 2006  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	50.80	655.24
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.00	-41.25

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	50.80	655.24
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.00	-41.25

FILE 'REGISTRY' ENTERED AT 14:06:41 ON 07 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 6 DEC 2006 HIGHEST RN 914980-83-9  
DICTIONARY FILE UPDATES: 6 DEC 2006 HIGHEST RN 914980-83-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:



<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\105121325.str

Young, Shawquia, Page 1

13/12/2006,10521325b.trn




chain nodes :  
10 11 12 13  
ring nodes :  
1 2 3 4 5 6 7 8 9  
chain bonds :  
7-12 9-10 10-11 12-13  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9  
exact/norm bonds :  
5-7 6-9 7-8 7-12 8-9 9-10 10-11  
exact bonds :  
12-13  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:CLASS 12:CLASS 13:CLASS

L10 STRUCTURE UPLOADED

=> d l10  
L10 HAS NO ANSWERS  
L10 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l10  
SAMPLE SEARCH INITIATED 14:07:11 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 7 TO ITERATE

13/12/2006,10521325b.trn

100.0% PROCESSED            7 ITERATIONS            6 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*  
                             BATCH    \*\*COMPLETE\*\*  
PROJECTED ITERATIONS:            7 TO            298  
PROJECTED ANSWERS:                6 TO            266

L11                    6 SEA SSS SAM L10

=> s l10 full  
FULL SEARCH INITIATED 14:07:15 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED -            105 TO ITERATE

100.0% PROCESSED            105 ITERATIONS            58 ANSWERS  
SEARCH TIME: 00.00.01

L12                    58 SEA SSS FUL L10

=> file hcaplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	166.94	822.18
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-41.25

FILE 'HCAPLUS' ENTERED AT 14:07:19 ON 07 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 7 Dec 2006    VOL 145 ISS 24  
FILE LAST UPDATED: 6 Dec 2006    (20061206/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l12  
L13                    4 L12  
  
=> d ed abs ibib hitstr 1-4

L13 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 31 Aug 2006  
 GI



AB Indole compds. represented by the general formula (I) or salts or solvates thereof or prodrugs thereof [R11, R12 = substituents; two of R51, R52, and R53 are independently groups having a (un)protected acidic group and the remaining one group is H or a substituent; R3 = a substituent; m = an integer of 0-4; n = an integer of 0-2; p = 0, 1] are prepared. These compds. have a leukotriene receptor antagonistic effect and are expected to be more effective than those of the leukotriene receptor antagonists currently used in clin. medicine. They are therefore useful as agents for prevention and/or treatment of a leukotriene-mediated disease such as a respiratory disease, e.g., bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g., interstitial pneumonia), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g., acute sinusitis, chronic sinusitis), and pulmonary fibrosis, and as expectorants or antitussives. Thus, Me 4-bromo-1-(4-methoxy-4-oxobutyl)-1H-indole-3-carboxylate was coupled with 4-vinylphenyl acetate in the presence of palladium acetate and tris(2-methylphenyl)phosphine in a solution of Et3N in MeCN at 85° for 2 h to give Me 4-[(E)-2-[4-(acetoxy)phenyl]ethenyl]-1-(4-methoxy-4-oxobutyl)-1H-indole-3-carboxylate. The latter compound was deacetylated by treatment with K2CO3 in a mixture of methanol and THF at room temperature for 2 h and etherified with 1-chloro-4-phenylbutane in the presence of NaI and K2CO3 in DMF at 95° for 2 h to give Me 1-(4-methoxy-4-oxobutyl)-4-[(E)-2-[4-(4-phenylbutoxy)phenyl]ethenyl]-1H-indole-3-carboxylate which was stirred with a mixture of 1 M aqueous NaOH solution, THF, and MeOH and acidified with 1.2 M aqueous HCl solution to give 1-(3-carboxypropyl)-4-[(E)-2-[4-(4-phenylbutoxy)phenyl]ethenyl]-1H-indole-3-carboxylic acid.

4-[(1-(Carboxymethyl)-7-[(E)-2-[4-(4-phenoxybutoxy)phenyl]ethenyl]-1H-indol-3-yl)butanoic acid at 10 mg/kg p.o. in vivo inhibited the ovalbumin-induced constriction of airway in guinea pigs. A tablet and an ampule formulation containing 4-[3-(carboxymethyl)-4-[(E)-2-[4-(4-


L13 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 phenylbutoxy)phenyl]ethenyl]-1H-indol-1-yl)butanoic acid were described.  
 ACCESSION NUMBER: 2006:086288 HCAPLUS  
 DOCUMENT NUMBER: 145:292868  
 TITLE: Preparation of indole derivatives as leukotriene receptor antagonists  
 INVENTOR(S): Takeuchi, Jun; Nakayama, Yoshisuke; Fujita, Manabu  
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 353pp.  
 CODEN: PIXAD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006/090817	A1	20060831	WO 2006-JP303374	20060224
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CM, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KH, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, TP, BJ, CF, CG, CI, CM, GA, GH, GG, GM, ML, MR, NE, SH, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.: JP 2005-51392 A 20050225 JP 2005-352787 A 20051207				

OTHER SOURCE(S): MARPAT 145:292868  
 IT 908137-43-9P 908137-44-UP  
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of indole derivative as leukotriene receptor antagonists for prevention and/or treatment of respiratory diseases)  
 RN 908137-43-9 HCAPLUS  
 CN 1H-indole-1-acetic acid, 3-[(3-carboxypropyl)sulfonyl]-7-[(E)-2-[4-(4-phenoxybutoxy)phenyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


L13 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 908137-44-0 HCAPLUS  
 CN 1H-Indole-1-acetic acid, 3-[(3-carboxypropyl)sulfonyl]-7-[(E)-2-[4-(4-(2,3-difluorophenoxy)butoxy)phenyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

PAGE 1-A



L13 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



REFERENCE COUNT: 49  
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L13 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN  
ED Entered STN: 08 Jun 2006  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to indoles and related compds. of formula I, which are modulators of peroxisome proliferator-activated receptors (PPARs).

In compds. I, U, V, W, X, and Y are independently selected from N and (un)substituted C; R1 is selected from (un)substituted carboxyl and carboxylic acid isosteres; R2 is H, (un)substituted lower alkyl, (un)substituted lower alkenyl, (un)substituted cycloalkyl, (un)substituted heterocyclyl, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted arylsulfonyl, etc.; R3 and R4 are independently selected from H, (un)substituted lower alkyl, (un)substituted cycloalkyl, (un)substituted heterocyclyl, (un)substituted aryl, (un)substituted heteroaryl, etc.; or R3 and R4 may combine to form a 3- to 7-membered (un)substituted cycloalkyl or 3- to 7-membered (un)substituted heterocyclyl; and n is 0, 1, or 2; provided that no more than two of U, V,

W, and Y are N. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound of formula I and a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment or prevention of a disease or condition for which PPAR modulation provides a therapeutic benefit. Arylsulfonylation of 6-methoxyindole with 4-tolylthiol and oxidation gave sulfonylindole II,

which underwent alkylation with Me 3-bromopropionate and ester hydrolysis to give indolepropionic acid III. Some compds. of the invention express

EC50 values below 1 nM for at least one PPAR subtype and some compds. exhibit at least 5-fold selectivity for one subtype over other subtypes of receptors (no specific data).

ACCESSION NUMBER: 2006:538077 HCAPLUS

DOCUMENT NUMBER: 145:45938

TITLE: Indoles and related derivatives as PPAR modulators, their preparation, pharmaceutical compositions, and use in therapy

INVENTOR(S): Lin, Jack; Ibrahim, Prabha N.; Artis, Dean R.; Zhang, Chao; Wang, Weiru; Shi, Shenghua

PATENT ASSIGNEE(S): Plexxikon, Inc., USA

SOURCE: PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006060535	A2	20060608	WO 2005-US43412	20051129

L13 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN  
ED Entered STN: 09 May 2005  
GI



AB Title compds. [I; R1-R4 = H, halo, alkyl, alkoxy, OH, NO2, cyano, N(R)2, SO2R9, CON(R)2, etc.; R5 = H, alkyl; R6 = H, alkyl; R5R6C = C3-7 cycloalkyl; R7 = H, alkyl; n = 1, 2; X = bond, NR9; R8 = (substituted) alkyl, alkenyl, alkynyl, biphenyl, (bi- or tricyclic) heteroaryl, Ph, naphthyl; with provisos], were prepared for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis. Thus, (5-fluoro-2-methyl-3-phenylmethanesulfonyl-1H-indol-1-yl)acetic acid (general preparation given) showed CRTH2 binding with Ki = 6 nM.

ACCESSION NUMBER: 2005:395269 HCAPLUS

DOCUMENT NUMBER: 142:463597

TITLE: Preparation of indol-1-ylacetates as chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) antagonists

INVENTOR(S): Middlemiss, David; Ashton, Mark Richard; Boyd, Edward Andrew; Brookfield, Frederick Arthur; Armer, Richard Edward

PATENT ASSIGNEE(S): Oxigen Limited, UK

SOURCE: PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040114	A1	20050506	WO 2004-GB4336	20041013

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004283139 A1 20050506 AU 2004-283139 20041013  
CA 2542716 AA 20050506 CA 2004-2542716 20041013  
EP 1675826 A1 20060705 EP 2004-768867 20041013  
R: AT, BE, CH, DE, DK, EE, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,

L13 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

WO 2006060535 A3 20060914

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006135540 A1 20060622 US 2005-289781 20051129

PRIORITY APPLN. INFO.: US 2004-631893P P 20041130


US 2005-715258P P 20050907

OTHER SOURCE(S): MARPAT 145:45938  
IT 889129-65-1P, 2-(6-Methoxy-3-((4-methoxybenzene)sulfonyl)indol-1-yl)acetic acid  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of indoles and related compds. as PPAR modulators)

RN 889129-65-1 HCAPLUS

CN 1H-indole-1-acetic acid, 6-methoxy-3-((4-methoxyphenyl)sulfonyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN 1867547 A 20061122 CN 2004-80030071 20041013

NO 2006001454 A 20060706 NO 2006-1454 20060330

PRIORITY APPLN. INFO.: GB 2003-24084 A 20031014

GB 2004-716 A 20040114


WO 2004-GB4336 W 20041013

OTHER SOURCE(S): MARPAT 142:463597  
IT 851460-57-6P 851460-58-7P 851460-59-8P  
851460-60-1P 851460-61-2P 851460-62-3P  
851460-63-4P 851460-64-5P 851460-65-6P  
851460-66-7P 851460-67-8P 851460-68-9P  
851460-69-0P 851460-70-3P 851460-71-4P  
851460-72-5P 851460-73-6P 851460-74-7P  
851460-75-8P 851460-76-9P 851460-77-0P  
851460-78-1P 851460-79-2P 851460-80-5P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of indolylacetates as CRTH2 antagonists)


RN 851460-57-6 HCAPLUS

CN 1H-indole-1-acetic acid, 3-((1,1'-biphenyl)-4-ylsulfonyl)-5-fluoro-2-methyl- (9CI) (CA INDEX NAME)



RN 851460-58-7 HCAPLUS


CN 1H-indole-1-acetic acid, 3-((carboxymethyl)sulfonyl)-5-fluoro-2-methyl- (9CI) (CA INDEX NAME)




RN 851460-59-8 HCAPLUS

CN 1H-indole-1-acetic acid, 3-((2-amino-2-oxoethyl)sulfonyl)-5-fluoro-2-methyl- (9CI) (CA INDEX NAME)


L13 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 851460-60-1 HCAPLUS  
CN 1H-Indole-1-acetic acid, 5-fluoro-2-methyl-3-[(2-methylsulfonyl)ethylsulfonyl]- (9CI) (CA INDEX NAME)




RN 851460-61-2 HCAPLUS  
CN 1H-Indole-1-acetic acid, 3-(2-benzothiazolylsulfonyl)-5-fluoro-2-methyl- (9CI) (CA INDEX NAME)




RN 851460-62-3 HCAPLUS  
CN 1H-Indole-1-acetic acid, 3-(2-benzothiazolylsulfonyl)-5-fluoro-2-methyl- (9CI) (CA INDEX NAME)


L13 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 851460-66-7 HCAPLUS  
CN 1H-Indole-1-acetic acid, 3-[[[4-chlorophenyl]amino]sulfonyl]-5-fluoro-2-methyl- (9CI) (CA INDEX NAME)



RN 851460-67-8 HCAPLUS  
CN 1H-Indole-1-acetic acid, 3-[[[3-chlorophenyl]amino]sulfonyl]-5-fluoro-2-methyl- (9CI) (CA INDEX NAME)




RN 851460-68-9 HCAPLUS  
CN 1H-Indole-1-acetic acid, 5-fluoro-3-[[[4-fluorophenyl]amino]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 851460-69-0 HCAPLUS  
CN 1H-Indole-1-acetic acid, 3-[[[2-chlorophenyl]amino]sulfonyl]-5-fluoro-2-


L13 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 851460-63-4 HCAPLUS  
CN 1H-Indole-1-acetic acid, 5-fluoro-2-methyl-3-(2-quinolinylsulfonyl)- (9CI) (CA INDEX NAME)




RN 851460-64-5 HCAPLUS  
CN 1H-Indole-1-acetic acid, 5-fluoro-2-methyl-3-(8-quinolinylsulfonyl)- (9CI) (CA INDEX NAME)




RN 851460-65-6 HCAPLUS  
CN 1H-Indole-1-acetic acid, 5-fluoro-2-methyl-3-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)


L13 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 851460-70-3 HCAPLUS  
CN 1H-Indole-1-acetic acid, 5-fluoro-2-methyl-3-[[[phenylmethyl]amino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 851460-71-4 HCAPLUS  
CN 1H-Indole-1-acetic acid, 5-fluoro-3-[[[4-methoxyphenyl]amino]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 851460-72-5 HCAPLUS  
CN 1H-Indole-1-acetic acid, 5-fluoro-3-[[[4-methoxyphenyl]amino]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




L13 ANSWER 3 OF 4 HCAPIUS COPYRIGHT 2006 ACS on STN (Continued)


RN 851460-73-6 HCAPIUS  
 CN 1H-Indole-1-acetic acid, 5-fluoro-2-methyl-3-[(phenylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 851460-74-7 HCAPIUS  
 CN 1H-Indole-1-acetic acid, 3-[[[(3,4-dichlorophenyl)methyl]amino]sulfonyl]-5-fluoro-2-methyl- (9CI) (CA INDEX NAME)




RN 851460-75-8 HCAPIUS  
 CN 1H-Indole-1-acetic acid, 5-fluoro-3-[[[(3-methoxyphenyl)amino]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 851460-76-9 HCAPIUS  
 CN 1H-Indole-1-acetic acid, 5-fluoro-2-methyl-3-[[[(3-methylphenyl)amino]sulfonyl]- (9CI) (CA INDEX NAME)

L13 ANSWER 3 OF 4 HCAPIUS COPYRIGHT 2006 ACS on STN (Continued)




RN 851460-80-5 HCAPIUS  
 CN 1H-Indole-1-acetic acid, 5-fluoro-2-methyl-3-[[[(3-pyridinylamino)sulfonyl]- (9CI) (CA INDEX NAME)



IT 851460-91-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


RN 851460-91-8 HCAPIUS  
 CN 1H-Indole-1-acetic acid, 3-(butylsulfonyl)-5-fluoro-2-methyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


L13 ANSWER 3 OF 4 HCAPIUS COPYRIGHT 2006 ACS on STN (Continued)



RN 851460-77-0 HCAPIUS  
 CN 1H-Indole-1-acetic acid, 5-fluoro-2-methyl-3-[[[(4-methylphenyl)amino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 851460-78-1 HCAPIUS  
 CN 1H-Indole-1-acetic acid, 3-[[[(4-chlorophenyl)methyl]amino]sulfonyl]-5-fluoro-2-methyl- (9CI) (CA INDEX NAME)



RN 851460-79-2 HCAPIUS  
 CN 1H-Indole-1-acetic acid, 5-fluoro-2-methyl-3-[[[(methyl(phenylmethyl)amino)sulfonyl]- (9CI) (CA INDEX NAME)

L13 ANSWER 4 OF 4 HCAPIUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 26 Jan 2004  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to substituted indoles I (wherein: n = 1, 2; R1 = halogen, CN, NO2, SO2R4, OR4, SR4, S(O)R4, (hetero)aryl, (un)substituted alk(en/yn)yl, etc.; R2 = H, halogen, CN, SO2R4, C(O)R4, (un)substituted alkyl, etc.; R3 = (hetero)aryl optionally containing N, S, or O, (un)substituted with halogen, CN, NO2, SO2R4, OH, OR4, SR4, S(O)R4, (un)substituted alk(en/yn)yl, etc.; R4 = (hetero)aryl or alkyl (un)substituted by halogen, (hetero)aryl, etc.) as modulators of CRTH2 receptor activity useful in treatment of diseases (such as respiratory disorders) which are caused by excessive or unregulated production of PGD2.


For instance, compound II (example 2, pIC50 = 8.1) was prepared via heterocyclization of 4-ClC6H4NH2 with 4-ClC6H4SCH2C(O)CH3, transformation of obtained indole III to the Me N-acetate analog of III, subsequent S-oxidation and hydrolysis of ester.

ACCESSION NUMBER: 2004:60469 HCAPIUS  
 DOCUMENT NUMBER: 140:111276  
 TITLE: Preparation of indole-3-sulphur derivatives and their use in the treatment of respiratory disorders  
 INVENTOR(S): Bonnett, Roger; Dickinson, Mark; Rasul, Rukhsana; Sangane, Hitesh; Teague, Simon  
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.  
 SOURCE: PCT Int. Appl., 59 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007451	A1	20040122	WO 2003-SE1216	20030715
M:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BO, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TR, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2492445	AA	20040122	CA 2003-2492445	20030715
AU 2003251260	A1	20040202	AU 2003-251260	20030715
BR 2003012729	A	20050510	BR 2003-12729	20030715
EP 1551802	A1	20050713	EP 2003-764279	20030715
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1678579	A	20051005	CN 2003-819971	20030715
JP 2005537265	T2	20051208	JP 2004-521364	20030715
NZ 537606	A	20060831	NZ 2003-537606	20030715
ZA 2005000170	A	20060222	ZA 2005-170	20050107


L13 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 NO 2005000828 A 20050405 NO 2005-828 20050216  
 US 2006111426 A1 20060525 US 2005-521325 20050815  
 PRIORITY APPLN. INFO.: SE 2002-2241 A 20020717  
 SE 2002-3713 A 20021213  
 WO 2003-SE1216 W 20030715

OTHER SOURCE(S): MARPAT 140:111276  
 IT 646514-88-7P, 3-[(3-Methoxyphenyl)thio]-2,5-dimethyl-1H-indol-1-acetic acid  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of indole-3-sulfur deriva. as modulators of CRTh2 receptor activity useful as drugs for treatment of respiratory disorders)  
 RN 646514-88-7 HCAPLUS  
 CN 1H-Indole-1-acetic acid, 3-[(3-methoxyphenyl)sulfonyl]-2,5-dimethyl- (9CI)  
 (CA INDEX NAME)




IT 646514-29-6P 646514-32-1P, 5-Chloro-3-[(4-chlorophenyl)sulfonyl]-2-methyl-1H-indole-1-acetic acid  
 646514-37-6P, 6-Chloro-3-[(4-chlorophenyl)sulfonyl]-2-methyl-1H-indole-1-acetic acid 646514-42-3P, 7-Chloro-3-[(4-chlorophenyl)sulfonyl]-2-methyl-1H-indole-1-acetic acid  
 646514-47-8P, 5-Chloro-3-[(4-chlorophenyl)sulfonyl]-4-cyano-2-methyl-1H-indole-1-acetic acid 646514-52-5P, 5-Chloro-3-[(4-chlorophenyl)sulfonyl]-6-cyano-2-methyl-1H-indole-1-acetic acid 646514-56-9P, 3-[(4-chlorophenyl)sulfonyl]-2,5-dimethyl-1H-indole-1-acetic acid 646514-60-5P, 3-[(4-chlorophenyl)sulfonyl]-4-(ethylsulfonyl)-7-methoxy-2-methyl-1H-indole-1-acetic acid  
 646514-67-2P, 3-[(4-chlorophenyl)sulfonyl]-5-cyano-2-methyl-1H-indole-1-acetic acid 646514-73-0P, 3-[(4-chlorophenyl)sulfonyl]-5-cyano-2-methyl-1H-indole-1-acetic acid 646514-79-6P, 4-Chloro-3-[(4-chlorophenyl)sulfonyl]-2-methyl-1H-indole-1-acetic acid 646514-91-2P, 3-[(2-chlorophenyl)sulfonyl]-2,5-dimethyl-1H-indol-1-acetic acid 646514-95-6P, 3-[(3-chlorophenyl)sulfonyl]-2,5-dimethyl-1H-indol-1-acetic acid 646514-98-9P, 3-[(4-cyanophenyl)sulfonyl]-2,5-dimethyl-1H-indole-1-acetic acid  
 646515-01-7P, 3-[(2-methylphenyl)sulfonyl]-2,5-dimethyl-1H-indol-1-acetic acid 646515-05-1P, 3-[(2-ethylphenyl)sulfonyl]-2,5-dimethyl-1H-indol-1-acetic acid 646515-09-5P,


L13 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 3-[(4-chlorophenyl)sulfonyl]-2-methyl-4-nitro-1H-indole-1-acetic acid 646515-15-3P, 4-(Acetylamino)-3-[(4-chlorophenyl)sulfonyl]-2-methyl-1H-indole-1-acetic acid 646515-23-3P,  
 3-[(4-chlorophenyl)sulfonyl]-2-methyl-4-[(methylsulfonyl)amino]-1H-indole-1-acetic acid 646515-31-3P, 3-[(4-chlorophenyl)sulfonyl]-4-(ethylamino)-2-methyl-1H-indole-1-acetic acid 646515-33-5P,  
 3-[(2,6-dichlorophenyl)sulfonyl]-2,5-dimethyl-1H-indole-1-acetic acid 646515-36-8P, 3-[(4-chlorophenyl)sulfonyl]-2-methyl-4-phenyl-1H-indole-1-acetic acid 646515-42-6P, 3-[(4-chlorophenyl)sulfonyl]-5-fluoro-2-methyl-1H-indole-1-acetic acid ammonium salt  
 646515-50-6P, 3-[(3-chlorophenyl)sulfonyl]-5-fluoro-2-methyl-1H-indole-1-acetic acid ammonium salt 646515-54-0P, 5-Fluoro-2-methyl-3-[(4-(trifluoromethyl)phenyl)sulfonyl]-1H-indole-1-acetic acid ammonium salt 646515-59-5P, 3-[(4-chlorophenyl)sulfonyl]-5-fluoro-2-methyl-1H-indole-1-acetic acid 646515-61-9P, 3-[(3-chlorophenyl)sulfonyl]-5-fluoro-2-methyl-1H-indole-1-acetic acid 646515-63-1P, 5-Fluoro-2-methyl-3-[(4-(trifluoromethyl)phenyl)sulfonyl]-1H-indole-1-acetic acid 646518-01-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of indole-3-sulfur deriva. as modulators of CRTh2 receptor activity useful as drugs for treatment of respiratory disorders)  
 RN 646514-29-6 HCAPLUS  
 CN 1H-Indole-1-acetic acid, 3-[(4-chlorophenyl)sulfonyl]-2,5-dimethyl- (9CI)  
 (CA INDEX NAME)




RN 646514-32-1 HCAPLUS  
 CN 1H-Indole-1-acetic acid, 5-chloro-3-[(4-chlorophenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




L13 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RN 646514-37-6 HCAPLUS  
 CN 1H-Indole-1-acetic acid, 6-chloro-3-[(4-chlorophenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 646514-42-3 HCAPLUS  
 CN 1H-Indole-1-acetic acid, 7-chloro-3-[(4-chlorophenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 646514-47-8 HCAPLUS  
 CN 1H-Indole-1-acetic acid, 5-chloro-3-[(4-chlorophenyl)sulfonyl]-4-cyano-2-methyl- (9CI) (CA INDEX NAME)




RN 646514-52-5 HCAPLUS  
 CN 1H-Indole-1-acetic acid, 5-chloro-3-[(4-chlorophenyl)sulfonyl]-6-cyano-2-methyl- (9CI) (CA INDEX NAME)




L13 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RN 646514-56-9 HCAPLUS  
 CN 1H-Indole-1-acetic acid, 3-[(4-chlorophenyl)sulfonyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 646514-60-5 HCAPLUS  
 CN 1H-Indole-1-acetic acid, 3-[(4-chlorophenyl)sulfonyl]-4-(ethylsulfonyl)-7-methoxy-2-methyl- (9CI) (CA INDEX NAME)



RN 646514-67-2 HCAPLUS  
 CN 1H-Indole-1-acetic acid, 3-[(4-chlorophenyl)sulfonyl]-5-cyano-2-methyl- (9CI) (CA INDEX NAME)




RN 646514-73-0 HCAPLUS  
 CN 1H-Indole-1-acetic acid, 3-[(4-chlorophenyl)sulfonyl]-5-cyano-2-methyl- (9CI) (CA INDEX NAME)




13/12/2006,10521325b.trn


L13 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 646514-79-6 HCAPLUS  
CN 1H-Indole-1-acetic acid, 4-chloro-3-[(4-chlorophenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 646514-91-2 HCAPLUS  
CN 1H-Indole-1-acetic acid, 3-[(2-chlorophenyl)sulfonyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 646514-95-6 HCAPLUS  
CN 1H-Indole-1-acetic acid, 3-[(3-chlorophenyl)sulfonyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




L13 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 646515-15-3 HCAPLUS  
CN 1H-Indole-1-acetic acid, 4-(acetylamino)-3-[(4-chlorophenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 646515-23-3 HCAPLUS  
CN 1H-Indole-1-acetic acid, 3-[(4-chlorophenyl)sulfonyl]-2-methyl-4-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 646515-31-3 HCAPLUS  
CN 1H-Indole-1-acetic acid, 3-[(4-chlorophenyl)sulfonyl]-4-(ethylamino)-2-methyl- (9CI) (CA INDEX NAME)




RN 646515-33-5 HCAPLUS

L13 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 646514-98-9 HCAPLUS  
CN 1H-Indole-1-acetic acid, 3-[(4-cyanophenyl)sulfonyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 646515-01-7 HCAPLUS  
CN 1H-Indole-1-acetic acid, 2,5-dimethyl-3-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 646515-05-1 HCAPLUS  
CN 1H-Indole-1-acetic acid, 3-[(2-ethylphenyl)sulfonyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 646515-09-5 HCAPLUS  
CN 1H-Indole-1-acetic acid, 3-[(4-chlorophenyl)sulfonyl]-2-methyl-4-nitro- (9CI) (CA INDEX NAME)

L13 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 646515-36-8 HCAPLUS  
CN 1H-Indole-1-acetic acid, 3-[(2,6-dichlorophenyl)sulfonyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 646515-36-8 HCAPLUS  
CN 1H-Indole-1-acetic acid, 3-[(4-chlorophenyl)sulfonyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 646515-42-6 HCAPLUS  
CN 1H-Indole-1-acetic acid, 3-[(4-chlorophenyl)sulfonyl]-5-fluoro-2-methyl-, ammonium salt (9CI) (CA INDEX NAME)




● NH<sub>3</sub>

RN 646515-50-6 HCAPLUS  
CN 1H-Indole-1-acetic acid, 3-[(3-chlorophenyl)sulfonyl]-5-fluoro-2-methyl-, ammonium salt (9CI) (CA INDEX NAME)


L13 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

● NH<sub>3</sub>

RN 646515-54-0 HCAPLUS  
 CN 1H-Indole-1-acetic acid, 5-fluoro-2-methyl-3-[(4-(trifluoromethyl)phenyl)sulfonyl]-, ammonium salt (9CI) (CA INDEX NAME)


● NH<sub>3</sub>

RN 646515-59-5 HCAPLUS  
 CN 1H-Indole-1-acetic acid, 3-[(4-chlorophenyl)sulfonyl]-5-fluoro-2-methyl-, (9CI) (CA INDEX NAME)




RN 646515-61-9 HCAPLUS  
 CN 1H-Indole-1-acetic acid, 3-[(3-chlorophenyl)sulfonyl]-5-fluoro-2-methyl-, (9CI) (CA INDEX NAME)


L13 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 646515-63-1 HCAPLUS  
 CN 1H-Indole-1-acetic acid, 5-fluoro-2-methyl-3-[(4-(trifluoromethyl)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 646510-01-6 HCAPLUS  
 CN 1H-Indole-1-acetic acid, 3-[(4-chlorophenyl)sulfonyl]-5-cyano-2-methyl-, sodium salt (9CI) (CA INDEX NAME)



● Na

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT